Fredun Pharmaceuticals Ltd. BSE: 539730

Fredun Pharmaceuticals Ltd. Live Share Price Today, Share Analysis and Chart

681.75 6.40 (0.95%)

33.42% Fall from 52W High

2,017 BSE Volume

BSE 22 Apr, 2025 3:31 PM (IST)

Fredun Pharma Key Metrics

Default
All financials are in INR Cr and price data in INR
VIEW MORE
Loading... You have run out of DVM views! Check usage
Subscribe now to see details
Medium Financial Strength
45.0 / 100
Affordable Valuation
50.7 / 100
Technically Bearish
29.8 / 100
Falling Comet These stocks are with medium quality with average financials but with good valuation score. However, their weak technical aspects reduces the investor interest. View Similar Embed DVM

Fredun Pharmaceuticals Ltd. Live Price Chart

Fetching data ...

Fredun Pharma Stock Analysis

Fredun Pharma stock analysis with key metrics, changes, and trends.

Fredun Pharma MetricVALUECHANGE %TRENDANALYSIS
Annual Revenue₹349.07 Cr26.25%positive

Annual Revenue rose 26.25%, in the last year to ₹349.07 Cr. Its sector's average revenue growth for the last fiscal year was 11.87%.

Annual Net Profit₹15.62 Cr44.57%positive

Annual Net Profit rose 44.57% in the last year to ₹15.62 Cr. Its sector's average net profit growth for the last fiscal year was 26.81%.

Price to Earning Ratio17.12-positive

Price to Earning Ratio is 17.12, lower than its sector PE ratio of 40.48.

Stock Price₹681.75-10.61%negative

Stock Price fell 10.61% and underperformed its sector by 34.65% in the past year.

Quarterly Revenue₹102.7 Cr17.52%positive

Quarterly Revenue rose 17.52% YoY to ₹102.7 Cr. Its sector's average revenue growth YoY for the quarter was 9.98%.

Quarterly Net profit₹5.33 Cr26.27%positive

Quarterly Net profit rose 26.27% YoY to ₹5.33 Cr. Its sector's average net profit growth YoY for the quarter was 20.25%.

Debt to Equity Ratio0.87-positive

Debt to Equity Ratio of 0.87 is less than 1 and healthy. This implies that its assets are financed mainly through equity.

Return on Equity(ROE)12.86 %12.86%neutral

Return on Equity(ROE) for the last financial year was 12.86%, in the normal range of 10% to 20%.

Mutual Fund Holding0.00 %0%neutral

Mutual Fund Holding remained the same in the last quarter at 0%.

Promoter Share Holding48.93 %0%neutral

Promoter Share Holding stayed the same in the most recent quarter at 48.93%.

Interest Coverage Ratio2.85-positive

Interest Coverage Ratio is 2.85, higher than 1.5. This means that it is able to meet its interest payments comfortably with its earnings (EBIT).

Promoter Pledges0.00 %0%positive

Promoter Pledges are zero.

VIEW LESS


Loading data..

Earnings Conference Calls, Investor Presentations and Annual Reports

Annual Report Mar-2024
Annual Report Mar-2023
Annual Report Mar-2022
Annual Report Mar-2021
Annual Report Mar-2020
Annual Report Mar-2019
Annual Report Mar-2018
Annual Report Mar-2017
Annual Report Mar-2016

Fredun Pharmaceuticals Ltd. - Company Profile

What does Fredun Pharmaceuticals Ltd. do?

Fredun Pharmaceuticals in its Endeavour to move ahead has now ventured into manufacturing of dietary /herbal supplements, nutraceuticals, and other healthcare products along with Animal Healthcare products also with products ranging from allopathic formul

Website: www.fredungroup.com

Fredun Pharmaceuticals Ltd. Management structure

All Gross Remunerations are in INR
Fredun N Medhora
Executive Director, Managing Director, Chief Financial Officer
54 Lac
2024-3-31
Gross Remuneration
Year

Fredun Pharmaceuticals Ltd. Board of directors

All Gross Remunerations are in INR
Fredun N Medhora
Managing Director & CFO
54 Lac
2024
Gross Remuneration
Year
Daulat N Medhora
Chairperson & Joint MD
12 Lac
2024
Gross Remuneration
Year
Aspi N Raimalwala
Non-Exec. & Independent Dir.
1.12 Lac
2024
Gross Remuneration
Year
Rohinton Kanga
Non-Exec. & Independent Dir.
1.12 Lac
2024
Gross Remuneration
Year
Daisy Dsouza
Non-Exec. & Independent Dir.
16K
2024
Gross Remuneration
Year
Nariman B Medhora
Non Executive Director
-
2024
Gross Remuneration
Year

Fredun Pharmaceuticals Ltd. - company history

Incorporated in 1987 as a private limited company, Fredun Pharmaceuticals (FPL) was converted into a public limited company in Mar.'94. The Company was promoted by Nariman Medhora and Daulat N Medhora. The promoters initially established D N Pharma, a proprietary firm, for the manufacture and export of pharmaceutical formulations. Since 1993, D N Pharma's operations were phased out in order to switch over the business to FPL. The Company is well diversified in the business ranging from Formulations to Diagnostics to Consultancy. The Company has an unique range of products, from niche formulations , anti-diabetics to the latest antiretroviral and anti - Hypertensive products. It supplies finished formulations to over 42 Countries globally. It is associated with many Governments of different countries which have also realised the need for robust and consistent healthcare systems. The Company was set up with the objective of providing facilities for manufacturing and marketing of various pharmaceutical formulations like tablets, capsules, dry-syrups and ointments. It then set up a formulation unit at Palghar (Thane District), Maharashtra, which commenced commercial production in Aug.'94. FPL had been carrying out manufacturing operations on loan licence for reputed pharmaceutical companies like Cipla. It also manufactured for some merchant exporters, including Merind. In Apr.'96, the company came out with a public issue to register its products in the overseas market for exports; to part-finance the expansion of its business activities and to repay one of the term loans and unsecured loans to reduce the interest burden. Company is very much optimistic of revival of company's turnover by having excellent export order in hand. Company also in process of registering various drugs with different countires such as Nepal, Tanzaniya, Uganda & Sri Lanka. In 2013, Company launched 36 new products and filed 60 new products for registration. It launched a herbal dietary supplement in Africa. During 2015, three new granulation departments were introduced to the existing two departments. It launched 19 new products under the Cosmeceuticals OEM Division in 2023. It introduced 14 new products in the pet pharmaceuticals line, with another 36 in the works. It launched 16 products into the Pet Treat and Nutritional Supplement category.

Fredun Pharmaceuticals Ltd. FAQ

How is Fredun Pharmaceuticals Ltd. today?
Fredun Pharmaceuticals Ltd. today is trading in the green, and is up by 0.95% at 681.75.
Fredun Pharmaceuticals Ltd. is currently trading up 0.95% on an intraday basis. In the past week the stock rose 4.28%. stock has been down -2.70% in the past quarter and fell -10.61% in the past year. You can view this in the overview section.